TrialCancer immunology, immunotherapy : CII2023

Single-center phase 2 study of PD-1 inhibitor combined with DNA hypomethylation agent + CAG regimen in patients with relapsed/refractory acute myeloid leukemia.

Xiao-Ning Gao et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.